Report Published: "ImmunoCellular Therapeutics, Ltd. (IMUC) - Product Pipeline Analysis, 2013 Update"
ImmunoCellular Therapeutics, Ltd. (IMCU) is a clinical-stage biotechnology company. It develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. The company's immunotherapies product pipeline comprises ICT-140, ICT-121 and ICT-107. ICT-140 is a DC vaccine designed to target seven different ovarian cancer antigens. ICT-121, is being developed for the treatment of solid tumors and ICT-107 is being developed for the treatment of glioblastoma multiforme (GBM). IMCU is headquartered...
View full press release